These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37968517)

  • 1. Evaluation of optical coherence tomography biomarkers to differentiate favourable and unfavourable responders to intravitreal anti-vascular endothelial growth factor treatment in retinopathy of prematurity.
    Belenje A; Reddy RU; Parmeswarappa DC; Padhi TR; Subbarao B; Jalali S
    Eye (Lond); 2024 Apr; 38(6):1097-1103. PubMed ID: 37968517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor.
    Barry GP; Yu Y; Ying GS; Tomlinson LA; Lajoie J; Fisher M; Binenbaum G;
    Ophthalmology; 2021 Aug; 128(8):1188-1196. PubMed ID: 33387554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
    Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Chandra P
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009734. PubMed ID: 29308602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of 'sawtooth shunt' following anti-vascular endothelial growth factor for aggressive posterior retinopathy of prematurity.
    Padhi TR; Das T; Kaur P; Sutar S; Khalsa A; Modi R; Ali H; Pradhan L; Jalali S
    Int Ophthalmol; 2020 Apr; 40(4):1007-1015. PubMed ID: 31925658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal Bevacizumab for Zone II Retinopathy of Prematurity.
    Larrañaga-Fragoso P; Peralta J; Bravo-Ljubetic L; Pastora N; Abelairas-Gómez J
    J Pediatr Ophthalmol Strabismus; 2016 Nov; 53(6):375-382. PubMed ID: 27537247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27 month follow-up results from Turkey.
    Yetik H; Gunay M; Sirop S; Salihoglu Z
    Graefes Arch Clin Exp Ophthalmol; 2015 Oct; 253(10):1677-83. PubMed ID: 25501298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study protocol for prognosis and treatment strategy of peripheral persistent avascular retina after intravitreal anti-VEGF therapy in retinopathy of prematurity.
    Yu Y; Wang J; Chen F; Chen W; Jiang N; Xiang D
    Trials; 2020 Jun; 21(1):493. PubMed ID: 32513245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactivation of retinopathy of prematurity six years after intravitreal injection of bevacizumab.
    Yasin A; Sinha S; Smith R; Jain SF; Hejkal T; Rychwalski P
    J AAPOS; 2023 Aug; 27(4):236-239. PubMed ID: 37451499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Vitrectomy and Anti-VEGF Treatment for Stage 4 Retinopathy of Prematurity With Extensive Neovascular Proliferation.
    Chandra P; Kumawat D; Agarwal D; Chawla R
    J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):61-66. PubMed ID: 31972043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiographic Review of Choroidal Involution in Eyes with Retinopathy of Prematurity Treated with Bevacizumab.
    Islam Y; Andersen L; Agarwal-Sinha S
    Ophthalmic Res; 2022; 65(2):229-236. PubMed ID: 33113546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity.
    Tahija SG; Hersetyati R; Lam GC; Kusaka S; McMenamin PG
    Br J Ophthalmol; 2014 Apr; 98(4):507-12. PubMed ID: 24403566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morphological outcome and indication for laser following intravitreal bevacizumab monotherapy for posterior retinopathy of prematurity.
    Sindal MD; Nagesha CK; Yadav D; Fazal R
    Lasers Med Sci; 2022 Jul; 37(5):2501-2508. PubMed ID: 35106690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-vascular Endothelial Growth Factor Treatment of Retinopathy of Prematurity: Efficacy, Safety, and Anatomical Outcomes.
    Kang HG; Choi EY; Byeon SH; Kim SS; Koh HJ; Lee SC; Kim M
    Korean J Ophthalmol; 2018 Dec; 32(6):451-458. PubMed ID: 30549468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of intravitreal aflibercept monotherapy in retinopathy of prematurity evaluated by periodic fluorescence angiography and optical coherence tomography.
    Vural A; Perente İ; Onur İU; Eriş E; Seymen Z; Hergünsel GO; Salihoğlu Ö; Yiğit FU
    Int Ophthalmol; 2019 Oct; 39(10):2161-2169. PubMed ID: 30478752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extending Peripheral Retinal Vascularization in Retinopathy of Prematurity Through Regulation of VEGF Signaling.
    Sauer L; Chandler M; Hartnett ME
    Am J Ophthalmol; 2024 Apr; 260():190-199. PubMed ID: 38141904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
    Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
    Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Refractive outcome of intravitreal bevacizumab injection in comparison to spontaneous regression of retinopathy of prematurity (ROP).
    Etezad Razavi M; Shoeibi N; Hassanzadeh S; Kianmehr S; Bakhtiari E
    Strabismus; 2020 Mar; 28(1):49-54. PubMed ID: 31790628
    [No Abstract]   [Full Text] [Related]  

  • 19. Reactivation of retinopathy of prematurity after ranibizumab treatment.
    Wong RK; Hubschman S; Tsui I
    Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LONG-TERM EFFECTS OF ANTI-VEGF MONOTHERAPY FOR RETINOPATHY OF PREMATURITY ON THE RETINAL AND REFRACTIVE DEVELOPMENT OF EYE.
    Sukgen EA; Atalay HT; Özdek Ş
    Retina; 2022 Nov; 42(11):2194-2202. PubMed ID: 35962999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.